Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Data on Endometriosis Discussed by Researchers at AbbVie (Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:05pm CEST

Data on Endometriosis Discussed by Researchers at AbbVie (Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women)

By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Uterine Diseases and Conditions - Endometriosis have been published. According to news reporting originating in North Chicago, Illinois, by NewsRx journalists, research stated, "To estimate the prevalence of diagnosed endometriosis (DE) in women in the United States and assess the associated symptomatic burden. An online, cross-sectional survey of women aged 18-49 years was conducted from August 6, 2012, through November 14, 2012."

The news reporters obtained a quote from the research from AbbVie, "Survey data (weighted by age, race, education, income, geographical distribution, and propensity score) were used to estimate the prevalence and symptomatic burden of DE in women in the United States. Weighted logistic regressions were used to assess differences in symptom burden between women with and without endometriosis. The prevalence of DE was estimated at 6.1% (2,922 of 48,020 women surveyed); 52.7% of women were 18-29 years of age when they were diagnosed with endometriosis. Most (86.2%) women experienced symptoms before diagnosis. More women with (vs. without) DE had menstrual pelvic pain/ cramping (52.7 vs. 45.2%), non-menstrual pelvic pain/cramping (36.7 vs. 14.3%), infertility (11.6 vs. 3.4%), and dyspareunia (29.5 vs. 13.4%). Women with endometriosis were also more likely to report severe symptoms (OR (95% CI) 2.7 (2.3-3.1) for menstrual pelvic pain/cramping, 2.2 (1.7-2.9) for non-menstrual pelvic pain/cramping, and 2.4 (1.8-3.2) for dyspareunia)."

According to the news reporters, the research concluded: "The prevalence of DE among US women is notable, and affected women experience a substantial symptom burden."

For more information on this research see: Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women. Gynecologic and Obstetric Investigation, 2017;82(5):453-461. Gynecologic and Obstetric Investigation can be contacted at: Karger, Allschwilerstrasse 10, Ch-4009 Basel, Switzerland. (Karger - www.karger.com/; Gynecologic and Obstetric Investigation - content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223845)

Our news correspondents report that additional information may be obtained by contacting A.M. Soliman, AbbVie Inc, Hlth Econ & Outcomes Res, North Chicago, IL 60064, United States (see also Uterine Diseases and Conditions - Endometriosis).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1159/000452660. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: North Chicago, Illinois, United States, North and Central America, Female Urogenital Diseases and Conditions, Pelvic Pain, Diagnostics and Screening, Female Genital Diseases and Conditions, Physiological Sexual Dysfunction, Uterine Diseases and Conditions, Women's Health, Endometriosis, Dyspareunia, AbbVie.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
07/14ABBVIE : Announces Submission Of Supplemental New Drug Application To US FDA For..
AQ
07/13ABBVIE : Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer Diffuse L..
AQ
07/13ICER panel votes against elagolix for endometriosis
AQ
07/12ABBVIE : Studies from AbbVie Update Current Data on Alzheimer Disease (Digital t..
AQ
07/12ABBVIE : to Host Second-Quarter 2018 Earnings Conference Call
AQ
07/12ABBVIE : Announces Submission of Supplemental New Drug Application to US FDA for..
PU
07/12ABBVIE : Ex-dividend day for
FA
07/11ABBVIE : Says Study of Imbruvica in Type of Lymphoma Didn't Meet Primary Endpoin..
DJ
07/11ABBVIE : Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Can..
PR
07/11ABBVIE : Ex-Dividend Alert: AbbVie Has Raised its Dividend By 140% Since 2013; W..
AC
More news
News from SeekingAlpha
07/15YOUR DAILY PHARMA SCOOP : Zogenix Zooms, Zynerba's Changing Fortunes, AbbVie Pro.. 
07/13March To Freedom Fund Mid-Year Review 
07/133 THINGS IN BIOTECH, JULY 13 : AbbVie Swings, And AbbVie Also Misses 
07/13YOUR DAILY PHARMA SCOOP : ResTORbio Progresses, Roche Closer To Review, AbbVie F.. 
07/1343 Of 101 S&P 500 Stocks Show 'Safer' Dividends Yielding 3% To 5.55% For July 
Financials ($)
Sales 2018 32 946 M
EBIT 2018 14 429 M
Net income 2018 10 789 M
Debt 2018 29 248 M
Yield 2018 3,74%
P/E ratio 2018 13,99
P/E ratio 2019 12,48
EV / Sales 2018 5,54x
EV / Sales 2019 5,14x
Capitalization 153 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 113 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-0.08%153 340
MERCK KGAA-4.60%12 930
KYOWA HAKKO KIRIN CO LTD-0.99%11 282
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD97.15%11 237
JAZZ PHARMACEUTICALS PLC30.69%10 609
CONVATEC GROUP0.29%5 190